Skip to content

Re-evaluation of Zhui-Feng Tou-Gu capsule in the treatment of Osteoarthritis after marketing

Re-evaluation of Zhui-Feng Tou-Gu capsule in the treatment of Osteoarthritis after marketing

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2000002898
Enrollment
Unknown
Registered
2020-01-04
Start date
2020-01-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Sponsors

Temporarily not sure
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 years; (2) meet the diagnostic criteria of osteoarthritis.

Exclusion criteria

Exclusion criteria: (1) complications affecting joints, such as psoriasis, syphilitic neuropathy, Brown yellows, acute trauma, etc.; (2) bleeding tendency, gastrointestinal bleeding or other chronic bleeding disorders within the last month; (3) combined with tumor, bone tuberculosis, fracture and other cervical spine lesions or injuries; (4) pregnant, breast-feeding women; (5) allergic constitution or allergic to known ingredients of this drug; (6) complicated with serious diseases of heart, lung, liver, kidney, hematopoiesis and immune system.

Design outcomes

Primary

MeasureTime frame
Related symptoms and signs of osteoarthritis/osteodystrophy;X-ray changes;

Secondary

MeasureTime frame
WOMAC scale;

Countries

China

Contacts

Public ContactHe Yanlin

Hinye Pharmaceutical Co., Ltd

767567825@qq.com+86 15084974669

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026